Newsletter

Healthcare Stocks

Is AstraZeneca (AZN) a Buy After Its Failed Heart-Drug Trial?

AstraZeneca (NYSE:AZN) fell about 5% on Thursday, having plunged as much as 9% earlier in the day, after its closely watched Phase III CARDIO-TTRansform trial failed. At its worst, the setback wiped roughly £19 billion (about US$24 billion) off the company's value, though the shares clawed back some of that loss through the session. For…

ByUjjwal Maheshwari2 days ago

ReNerve (ASX:RNV) taps A$5m RiverFort facility as US sales ramp meets funding gap

ReNerve (ASX:RNV) secures a A$5 million RiverFort convertible facility to fund US sales expansion of its FDA-cleared NervAlign Nerve Cuff.

ByCharlie Youlden2 days ago

Eli Lilly (NYSE:LLY) Hits a Record High on Weight-Loss Drug Optimism: Buy or Too Late?

Eli Lilly (NYSE:LLY) hit a fresh all-time high on Tuesday, rising about 3% to near US$1,236 after JPMorgan lifted its price target on the stock to US$1,400. The drugmaker is now worth more than US$1.1 trillion, making it one of the largest healthcare companies on earth. The excitement is all about weight-loss drugs, but with…

ByUjjwal Maheshwari3 days ago

CurveBeam AI (ASX:CVB) prints two POs and 0.67 quarters of cash

CurveBeam AI (ASX:CVB) Q4 FY26 quarterly shows two HiRise POs, an 80% receipts jump, and a China NMPA clearance sitting at the heart of the story.

ByCharlie Youlden3 days ago

Cogstate (ASX:CGS) books US$89m of contracts and the H1 scare looks like noise

Cogstate (ASX:CGS) booked US$89m of contracts in FY26, up 116%, with US$48.3m already locked in for FY27 revenue.

ByCharlie Youlden3 days ago

Clinuvel Pharmaceuticals (ASX:CUV): Nearly 7 years on from the FDA’s approval of Scenesse, this company is now at a crossroads

Clinuvel Pharmaceuticals (ASX:CUV) is a perculiar company. It is a rare example of an Australian biotech that not only survived the long march from discovery to approval but did so with discipline, profitability and independence. Its 2019 FDA approval for Scenesse was the defining moment in its history, the point at which a decades‑long scientific…

ByNick Sundich4 days ago

Why Crinetics (NASDAQ:CRNX) Nearly Doubled Today After Vertex’s US$10 Billion Takeover

Crinetics (NASDAQ:CRNX) nearly doubled on Tuesday, soaring about 98% to near US$83, after Vertex Pharmaceuticals agreed to buy the company in an all-cash deal. Vertex is paying US$85.00 per share, valuing Crinetics at roughly US$10 billion. For shareholders, this is a massive overnight win. But the more useful question for investors now is not why…

ByUjjwal Maheshwari4 days ago

Botanix (ASX:BOT) locks European applicator patent to 2039 as Sofdra eyes exit from US

Botanix Pharmaceuticals (ASX:BOT) has secured a European patent Intention to Grant on the Sofdra applicator, running to May 2039 and reshaping its ex-US options.

ByCharlie Youlden4 days ago

Island Pharmaceuticals (ASX:ILA) gets Uganda green light to treat live Ebola outbreak with Galidesivir

Island Pharmaceuticals (ASX:ILA) secures Uganda approval to deploy Galidesivir into an active Bundibugyo Ebola outbreak under the WHO MEURI framework.

ByCharlie Youlden4 days ago

Healthcare Was the Worst ASX 200 Sector in FY26, But Here’s Why FY27 Will Be Better!

What was worst ASX 200 Sector in FY26? With a 36% decline, it was healthcare. Technology fell by a similar amount, but while you could argue you'd expect tech to fall given rising geopolitical tensions and interest rates, you wouldn't for health because the sector is normally defensive. While the theoretical reasons for thinking health is…

ByNick Sundich5 days ago

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Is AstraZeneca (AZN) a Buy After Its Failed Heart-Drug Trial?

ReNerve (ASX:RNV) taps A$5m RiverFort facility as US sales ramp meets funding gap

Eli Lilly (NYSE:LLY) Hits a Record High on Weight-Loss Drug Optimism: Buy or Too Late?

CurveBeam AI (ASX:CVB) prints two POs and 0.67 quarters of cash

Cogstate (ASX:CGS) books US$89m of contracts and the H1 scare looks like noise

Clinuvel Pharmaceuticals (ASX:CUV): Nearly 7 years on from the FDA’s approval of Scenesse, this company is now at a crossroads

Why Crinetics (NASDAQ:CRNX) Nearly Doubled Today After Vertex’s US$10 Billion Takeover

Botanix (ASX:BOT) locks European applicator patent to 2039 as Sofdra eyes exit from US

Island Pharmaceuticals (ASX:ILA) gets Uganda green light to treat live Ebola outbreak with Galidesivir

Healthcare Was the Worst ASX 200 Sector in FY26, But Here’s Why FY27 Will Be Better!

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here